December 19, 2018
With 2018 coming to an end, what's the biotech outlook? Next year will bring new investing opportunities for those in...
August 8, 2017
uniQure reported their financial results for the second quarter of 2017.
August 3, 2017
uniQure will regain the rights for their hemophilia B gene therapy as the Chiesi Group backs out from working partnership...
July 31, 2017
uniQure N.V. entered an agreement with Chiesi Group to reacquire the rights to co-develop and commercialize its hemophilia B gene...
July 11, 2017
uniQure N.V. presented new clinical data from the ongoing Phase I-II trial of AMT-060.
April 25, 2017
uniQure announced their gene therapy AMT-060, received PRIME designation from the European Medicines Agency.
April 20, 2017
uniQure N.V. announced it won't seek a marketing authorization renewal for Glybera in the European market, which is set to...